生活方式干预对非肥胖非酒精性脂肪性肝病患者有益
154例社区非酒精性脂肪性肝病(NAFLD)患者随机接受12个月生活方式干预或标准治疗,主要终点为第12个月经质子磁共振波谱评估的NAFLD缓解。非肥胖患者中干预组缓解率67% vs 对照组18%(p<0.001),肥胖患者为61% vs 21%(p<0.001)。非肥胖患者体重减轻3-5%即可使半数获得缓解,而肥胖患者需7-10%。
要点
- 非肥胖NAFLD患者生活方式干预后缓解率67%,显著高于对照组的18%(p<0.001)。
- 非肥胖患者体重减轻3-5%即可使半数获得NAFLD缓解,肥胖患者需7-10%。
- 至第6年,干预组非肥胖患者较对照组更可能维持体重减轻和丙氨酸氨基转移酶正常化。
核心结论
- 生活方式干预对非肥胖和肥胖NAFLD患者均有效。
- 体重减轻可预测非肥胖患者NAFLD缓解,但该人群适度体重减轻可能已足够。
研究设计与样本
- 随机对照试验,154例社区NAFLD患者随机分配至12个月生活方式干预(规律运动)组或标准治疗组,每组77例。
- 非肥胖定义采用亚洲体质指数(BMI)切点25 kg/m2;干预组和对照组分别有39例和38例基线BMI<25 kg/m2,分别有38例和39例基线BMI≥25 kg/m2。
- 主要终点为第12个月经质子磁共振波谱评估的NAFLD缓解;项目结束后前瞻性随访至第6年。
主要发现
- 非肥胖患者中干预组67% vs 对照组18%达到主要终点(p<0.001);肥胖患者中干预组61% vs 对照组21%(p<0.001)。
- 非肥胖患者中,生活方式干预、较低基线肝内甘油三酯、体重和腰围减少是与NAFLD缓解独立相关的因素。
- 非肥胖患者中半数经3-5%体重减轻即获NAFLD缓解,肥胖患者需7-10%体重减轻才能达到同样效果。
- 至第6年,干预组非肥胖患者较对照组更可能维持体重减轻和丙氨酸氨基转移酶正常化。
临床怎么用
- 作者结论认为生活方式干预对非肥胖和肥胖NAFLD患者均有效,非肥胖患者适度体重减轻可能已足够。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Around 10-20% of patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The benefit of weight reduction in such patients is unclear. We aim to study the efficacy of lifestyle intervention in non-obese patients with NAFLD and to identify factors that predict treatment response. METHODS: A total of 154 community NAFLD patients were randomised to a 12-month lifestyle intervention programme involving regular exercise, or to standard care. The primary outcome was remission of NAFLD at Month 12 by proton-magnetic resonance spectroscopy. After the programme, the patients were prospectively followed until Year 6. The Asian body mass index (BMI) cut-off of 25 kg/m2 was used to define non-obese NAFLD. RESULTS: Patients were assigned to the intervention (n = 77) and control (n = 77) groups (39 and 38 in each group had baseline BMI <25 and ≥25 kg/m2, respectively). More patients in the intervention group achieved the primary outcome than the control group regardless of baseline BMI (non-obese: 67% vs. 18%, p <0.001; obese: 61% vs. 21%, p <0.001). Lifestyle intervention, lower baseline intrahepatic triglyceride, and reduction in body weight and waist circumference were independent factors associated with remission of NAFLD in non-obese patients. Half of non-obese patients achieved remission of NAFLD with 3-5% weight reduction; the same could only be achieved in obese patients with 7-10% weight reduction. By Year 6, non-obese patients in the intervention group remained more likely to maintain weight reduction and alanine aminotransferase normalisation than the control group. CONCLUSIONS: Lifestyle intervention is effective in treating NAFLD in both non-obese and obese patients. Weight reduction predicts remission of NAFLD in non-obese patients, but a modest weight reduction may be sufficient in this population. LAY SUMMARY: Some patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The optimal management of such patients is unclear. In this long-term follow-up study of a clinical trial, we show that remission of NAFLD can be achieved in 67% of non-obese patients after lifestyle intervention. The majority of patients can achieve NAFLD remission with modest weight loss of 3-10%. Non-obese patients are also more likely than obese patients to maintain weight reduction and normal liver enzymes in the long run.
引用
- Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018. PMID: 30142427. doi:10.1016/j.jhep.2018.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。